IFF Recognized for Achieving Sustainability Leadership Throughout Transformational Year
12.1.2023 00:15:00 EET | Business Wire | Press release
IFF (NYSE:IFF) today announced it has qualified for the third consecutive year as a constituent of the Dow Jones Sustainability Indices (DJSI), a family of benchmarks widely regarded as one of the world’s leading tools for investors to integrate sustainability considerations into their portfolios to increase long-term shareholder value. Named to both the 2022 World Index and the North America Index, IFF is the only company in its industry to be included.
The S&P Global Corporate Sustainability Assessment (CSA) serves as the basis for the ESG scores that power the DJSI and its prestigious list of selected companies. IFF’s total CSA score places the Company among the top 10 percent of sustainability performers in the world, as assessed from among the 2,500 largest companies in the S&P Global Broad Market Index (BMI). Similarly, IFF ranks among the top 20 percent of the 600 largest companies in the S&P Global BMI in North America.
The distinction of achieving an annual place on the DJSI – and even increasing its score from the prior year – underscores IFF’s ongoing leadership position in environmental, social and governance (ESG) management, despite significantly increasing its size and complexity following the merger with DuPont’s Nutrition & Biosciences division in 2021. The Company’s CSA disclosures scored in 2022 were the first to reflect its post-merger performance and outcomes, including those based on an increase from nearly 14,000 employees to more than 24,000, and an expanded global footprint.
IFF was also recognized for leadership in corporate transparency and performance on climate change by global environmental non-profit CDP, securing a place on its 2022 ‘A List’ for climate change for the eighth consecutive year. Based on IFF’s post-merger data reported through CDP’s 2022 Climate Change questionnaire, IFF is one of a small number of companies out of nearly 15,000 scored that were named to the ‘A List’ for climate change, based on its actions to reduce emissions, mitigate climate risks and develop the low-carbon economy. IFF also received an “A-“ in CDP’s other two categories for action to protect water security risks and forests.
“We’re very proud to be recognized by S&P Global and CDP for our ESG excellence in 2022,” said Frank Clyburn, CEO, IFF. “We credit these achievements to the laser focus of our global team—striving to be the most sustainable company we can be—guided by our ambitious Do More Good Plan. We know we have more work to do in 2023 and beyond, but these external validations continue to inspire us and are a reminder that we’re heading in the right direction.”
IFF’s Do More Good Plan is a comprehensive ESG roadmap aligned with the Company’s purpose of applying science and creativity for a better world, organized by the four strategic focus areas of Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing and Transparency & Accountability.
The 2022 DJSI and CDP recognitions follow several other competitive ESG ratings IFF received during the year, including being:
- Awarded the 2022 EcoVadis Platinum sustainability rating for the second time, placing IFF among the top 1% of companies assessed;
- Named for the first time to the 2022 Bloomberg Gender Equality Index for its commitment to transparency and setting a new standard in gender-related data reporting; and
- Recertified for the second consecutive year by the Economic Dividends for Gender Equality (EDGE) at the Move level globally for its commitment to workplace diversity and intersectional issues.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005902/en/
Contact information
Paula Heinkel
Head of Global Communications
332-877-5339
Media.request@iff.com
Michael Bender
Director, Investor Relations
212-708-7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
